ORIFARM VMS acquired by STADA

CapVest‑backed STADA completed the acquisition of Orifarm Group A/S’s carved‑out vitamins, minerals and supplements (VMS) portfolio on 31 August 2026, marking the first transaction under the private‑equity owner’s majority stake. The divestiture transfers 16 established pharmacy‑channel brands—including Nycoplus in Norway, Apovit in Denmark, Magnecaps in Belgium and Vitrum in Poland—to STADA, expanding its consumer‑healthcare platform across the Nordics, Belgium and Central Europe. The acquisition reinforces STADA’s three‑pillar strategy of consumer health, generics and specialty pharma, providing a portfolio of local‑hero brands that hold leading market shares in their respective countries. By integrating the VMS brands into its dedicated consumer‑healthcare unit, STADA expects to capture additional shelf space in pharmacy chains and to benefit from economies of scale in procurement and marketing, while diversifying its revenue base with high‑margin OTC supplement sales that complement its generics and specialty offerings. For Orifarm, the transaction aligns with its long‑term strategy to concentrate on affordable pharmaceuticals and parallel‑traded medicines, shedding non‑core OTC assets while preserving its commitment to accessible healthcare. The deal was advised by Houlihan Lokey, serving as exclusive sell‑side financial advisor to Orifarm, and is subject to customary closing conditions and regulatory approvals.